Liliana Devizzi

4.4k total citations
59 papers, 1.9k citations indexed

About

Liliana Devizzi is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Liliana Devizzi has authored 59 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 23 papers in Genetics. Recurrent topics in Liliana Devizzi's work include Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Lung Cancer Treatments and Mutations (9 papers). Liliana Devizzi is often cited by papers focused on Lymphoma Diagnosis and Treatment (50 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Lung Cancer Treatments and Mutations (9 papers). Liliana Devizzi collaborates with scholars based in Italy, United States and Spain. Liliana Devizzi's co-authors include Simonetta Viviani, V. Bonfante, Gianni Bonadonna, Armando Santoro, Pinuccia Valagussa, Alessandro M. Gianni, Massimo Di Nicola, Paola Matteucci, Michele Magni and M. Zanini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Liliana Devizzi

57 papers receiving 1.8k citations

Peers

Countries citing papers authored by Liliana Devizzi

Since Specialization

Citations

This map shows the geographic impact of Liliana Devizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liliana Devizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liliana Devizzi more than expected).

Fields of papers citing papers by Liliana Devizzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liliana Devizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liliana Devizzi. The network helps show where Liliana Devizzi may publish in the future.

Co-authorship network of co-authors of Liliana Devizzi

This figure shows the co-authorship network connecting the top 25 collaborators of Liliana Devizzi. A scholar is included among the top collaborators of Liliana Devizzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liliana Devizzi. Liliana Devizzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study 2023 ·EClinicalMedicine ·Marek Trněný, Abraham Avigdor, Matthew McKinney, Shankara Paneesha, Björn E. Wahlin, John Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos‐Oreiro, David Belada, Liliana Devizzi, (unknown), Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch	3
2	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 2019 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Vittorio Stefoni, Alessia Castellino, Carlo Visco, Monica Tani, Maria Christina Cox, Roberto Marasca, Cristina Tecchio, Liliana Devizzi, Federico Monaco, Alessandra Romano, Chiara Rusconi, Luigi Rigacci, Claudia Castellino, Francesco Gaudio, Lisa Argnani, Pier Luigi Zinzani	2
3	TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy 2016 ·Blood ·Simonetta Viviani, Francesco Spina, Arabella Mazzocchi, (unknown), Flavio Crippa, Lucia Farina, Anna Guidetti, Massimo Di Nicola, Liliana Devizzi, Paola Matteucci, Michele Magni, Anna Dodero, Alessandro M. Gianni, Paolo Corradini	0
4	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice 2014 ·Leukemia & lymphoma ·Pier Luigi Zinzani, Luigi Rigacci, Maria Christina Cox, Liliana Devizzi, Alberto Fabbri, Alfonso Zaccaria, Francesco Zaja, Alice Di Rocco, Giuseppe Rossi, Sergio Storti, Pier Paolo Fattori, Lisa Argnani, S Tura, Umberto Vitolo	14
5	The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy 2013 ·American Journal of Hematology ·Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, Federica Delaini, Elena Oldani, Andrea Rossi, Anna Maria Barbui, Daniele Caracciolo, Marco Ladetto, Angela Gueli, (unknown), Roberto Passera, Liliana Devizzi, Caterina Patti, Alessandro M. Gianni, Corrado Tarella	53
6	Phase II study of sorafenib in patients with relapsed or refractory lymphoma 2012 ·British Journal of Haematology ·Anna Guidetti, Carmelo Carlo‐Stella, Silvia L. Locatelli, Walter Malorni, Marina Pierdominici, Cristiana Barbati, Roberta Mortarini, Liliana Devizzi, Paola Matteucci, Alfonso Marchianò, Rodolfo Lanocita, Lucia Farina, Anna Dodero, Corrado Tarella, Massimo Di Nicola, Paolo Corradini, Andrea Anichini, Alessandro M. Gianni	38
7	Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 2011 ·Cancer ·Anna Guidetti, Carmelo Carlo‐Stella, Marco Ruella, Rosalba Miceli, Liliana Devizzi, Silvia L. Locatelli, Arianna Giacomini, M. Testi, Stefano Buttiglieri, Alessandra Risso, Luigi Mariani, Massimo Di Nicola, Roberto Passera, Corrado Tarella, Alessandro M. Gianni	21
8	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) 2010 ·Annals of Oncology ·Annarita Conconi, Giovanni Martinelli, Armando López‐Guillermo, Pier Luigi Zinzani, Andrés J.M. Ferreri, Luigi Rigacci, Liliana Devizzi, Umberto Vitolo, Stefano Luminari, Franco Cavalli, Emanuele Zucca	54
9	CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 2010 ·Annals of Hematology ·Michael Mian, Luigi Marcheselli, Stefano Luminari, Massimo Federico, Maria Cantonetti, Andreas H. Sarris, Andrea Rossi, Alessandro Rambaldi, Marina Frontani, Liliana Devizzi, Alessandro M. Gianni, (unknown), Emilio Berti, Giovanni Martinelli, Richard Tsang, Andrés J.M. Ferreri, Graziella Pinotti, Enrico Pogliani, Emanuele Zucca, Sergio Cortelazzo	23
10	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience 2010 ·Leukemia & lymphoma ·Simonetta Viviani, Massimo Di Nicola, V. Bonfante, Antonio Di Stasi, Carmelo Carlo‐Stella, Paola Matteucci, Michele Magni, Liliana Devizzi, Pinuccia Valagussa, Alessandro M. Gianni	24
11	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 2009 ·European Journal of Nuclear Medicine and Molecular Imaging ·Claudio Chiesa, Francesca Botta, Angela Coliva, Marco Maccauro, Liliana Devizzi, Anna Guidetti, Carmelo Carlo‐Stella, Ettore Seregni, Massimo A. Gianni, Emilio Bombardieri	15
12	Dosimetry in Myeloablative ⁹⁰ Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results 2007 ·Cancer Biotherapy and Radiopharmaceuticals ·Claudio Chiesa, Francesca Botta, (unknown), Angela Coliva, Marco Maccauro, G Aliberti, (unknown), Liliana Devizzi, Anna Guidetti, Ettore Seregni, Alessandro M. Gianni, Emilio Bombardieri	17
13	High response rate and manageable toxicity with an intensive, short‐term chemotherapy programme for Burkitt's lymphoma in adults 2004 ·British Journal of Haematology ·Massimo Di Nicola, Carmelo Carlo‐Stella, Jacopo Mariotti, Liliana Devizzi, Maura Massimino, Antonello D. Cabras, Michele Magni, Paola Matteucci, Anna Guidetti, Lorenza Gandola, Alessandro M. Gianni	27
14	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B‐cell and diffuse large B‐cell histologies 2002 ·British Journal of Haematology ·Sergio Cortelazzo, Andrea Rossi, Elena Oldani, Teresio Motta, Roberto Giardini, Pier Luigi Zinzani, Emanuele Zucca, Henry Gómez, Andrés J.M. Ferreri, Graziella Pinotti, Claudio Chini, Liliana Devizzi, Alessandro M. Gianni, Franco Cavalli, Tiziano Barbui, (unknown)	9
15	Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial 1997 ·European Journal of Cancer ·Armando Santoro, V. Bonfante, Simonetta Viviani, M. Zanini, Liliana Devizzi, Héctor Soto Parrà, Anna Russo, F. Soncini, Flavio Villani, Pinuccia Valagussa, G. Bonadonna	1
16	Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. 1996 ·Journal of Clinical Oncology ·Simonetta Viviani, (unknown), (unknown), V. Bonfante, M. Zanini, Liliana Devizzi, F. Soncini, Pinuccia Valagussa	125
17	Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease 1994 ·Annals of Oncology ·Liliana Devizzi, Armando Santoro, V. Bonfante, Simonetta Viviani, Luca Balzarini, Pinuccia Valagussa, Gianni Bonadonna	66
18	Extended-field radiotherapy in favorable stage IA–IIA Hodgkin's disease (Prognostic role of stage) 1994 ·International Journal of Radiation OncologyBiologyPhysics ·M. Zanini, Simonetta Viviani, Armando Santoro, F. Soncini, V. Bonfante, Liliana Devizzi, (unknown), Maria Rita Castellani, (unknown), R Zucali, Franco Rilke, Alberto Banfi	6
19	Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP 1993 ·European Journal of Cancer ·V. Bonfante, Armando Santoro, Simonetta Viviani, R Zucali, Liliana Devizzi, M. Zanini, J. D. Tesoro Tess, (unknown), Alberto Banfi, G. Bonadonna	16
20	Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas 1992 ·Annals of Oncology ·Paolo G. Casali, Ugo Pastorino, (unknown), Liliana Devizzi, Alberto Azzarelli, Vittorio Quagliuolo, P. Bignami, Armando Santoro, Gianni Bonadonna	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact